Jazz Pharmaceuticals plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | $299.7M | $226.6M |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854.2M | $736.9M | $683.5M |
| Operating Income | $-430.2M | $716.6M | $578.6M | $-65.5M | $170.3M | $378.1M | $532.4M | $614.8M |
| Operating Margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% |
| Interest Expense | — | — | $32.8M | $32.8M | $89.9M | $87.6M | $62.5M | $56.7M |
| Pretax Income | $-627.9M | $470.4M | $297.9M | $-372.8M | $-112.8M | $275.1M | $454.3M | $529.5M |
| Income Tax Expense | $-272.4M | $-91.4M | $-119.9M | $-158.6M | $216.1M | $33.5M | $-73.2M | $80.2M |
| Net Income | $-356.1M | $560.1M | $414.8M | $-224.1M | $-329.7M | $238.6M | $523.4M | $447.1M |
| Net Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% | 24.2% | 23.6% |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 |
| Shares Outstanding (Basic) | 61.0M | 61.8M | 63.3M | 62.5M | 59.7M | 55.7M | 56.7M | 60.0M |
| Shares Outstanding (Diluted) | 61.0M | 66.0M | 72.1M | 62.5M | 59.7M | 56.5M | 57.6M | 61.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |